


PRMT5-IN-33

| | |
|--------------------|---|
| Cat. No.: | HY-162230 |
| Molecular Formula: | C ₂₅ H ₂₄ BrN ₅ O ₃ S |
| Molecular Weight: | 554.46 |
| Target: | Apoptosis; Histone Methyltransferase |
| Pathway: | Apoptosis; Epigenetics |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| Description | PRMT5-IN-33 (compound A8) is a selective, SAM-competitive PRMT5 inhibitors with IC ₅₀ of 10.9 nM. PRMT5-IN-33 induces apoptosis and inhibits proliferation of cells Z-138 and MOLM-13. PRMT5-IN-33 exhibits an antitumor activity ^[1] . | | | | | | | | | | | | | | | | | | | |
|-------------------------------------|--|--------------------------------------|--------------------------|------------------------------|--------------------------------|----------------------|------------|-------------------|----------------------|--------------------------|------------------------------|--------------------------------|----------------------|-------------------------------|----|------|------|------|------|------|
| IC₅₀ & Target | PRMT5 10.9 nM (IC ₅₀) | PRMT1 6.89 μM (IC ₅₀) | | | | | | | | | | | | | | | | | | |
| In Vitro | <p>PRMT5-IN-33 inhibits proliferation of cells Z-138 and MOLM-13, with IC₅₀s of 123.2 nM and 248.6 nM, respectively^[1]. PRMT5-IN-33 decreases levels of arginine symmetrical dimethylation (sDMA) in a dose-dependent manner^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Z-138 and MOLM-13</td> </tr> <tr> <td>Concentration:</td> <td>50-500 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited expression of sDMA.</td> </tr> </table> | | | | | | Cell Line: | Z-138 and MOLM-13 | Concentration: | 50-500 nM | Incubation Time: | 48 h | Result: | Inhibited expression of sDMA. | | | | | | |
| Cell Line: | Z-138 and MOLM-13 | | | | | | | | | | | | | | | | | | | |
| Concentration: | 50-500 nM | | | | | | | | | | | | | | | | | | | |
| Incubation Time: | 48 h | | | | | | | | | | | | | | | | | | | |
| Result: | Inhibited expression of sDMA. | | | | | | | | | | | | | | | | | | | |
| In Vivo | <p>PRMT5-IN-33 (60-120 mg/kg, i.g., twice a day for 13 days) inhibits the MOLM-13 xenograft tumor growth in a dose-dependent manner in BALB/c mice without a body weight loss^[1]. PRMT5-IN-33 (p.o., 10 mg/kg, single dosage) reveals a pharmacokinetic profiles in ICR mice^[1].</p> <p>Pharmacokinetic Analysis of PRMT5-IN-33 in ICR mice^[1]</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <thead> <tr> <th>route</th> <th>Dose (mg/kg)</th> <th>T_{max} (h)</th> <th>C_{max} (ng/mL)</th> <th>AUC_{0-t} (ng·h/mL)</th> <th>AUC_{0-inf} (ng·h/mL)</th> <th>T_{1/2} (h)</th> </tr> </thead> <tbody> <tr> <td>po</td> <td>10</td> <td>0.25</td> <td>6870</td> <td>6730</td> <td>6760</td> <td>1.17</td> </tr> </tbody> </table> | | | | | | route | Dose (mg/kg) | T _{max} (h) | C _{max} (ng/mL) | AUC _{0-t} (ng·h/mL) | AUC _{0-inf} (ng·h/mL) | T _{1/2} (h) | po | 10 | 0.25 | 6870 | 6730 | 6760 | 1.17 |
| route | Dose (mg/kg) | T _{max} (h) | C _{max} (ng/mL) | AUC _{0-t} (ng·h/mL) | AUC _{0-inf} (ng·h/mL) | T _{1/2} (h) | | | | | | | | | | | | | | |
| po | 10 | 0.25 | 6870 | 6730 | 6760 | 1.17 | | | | | | | | | | | | | | |

| | |
|-----------------|--|
| Animal Model: | MOLM-13 xenograft tumor in nude BALB/c mice ^[1] |
| Dosage: | 60-120 mg/kg |
| Administration: | intragastrical administration (i.g.), twice a day for 13 days |
| Result: | Exhibited a tumor growth inhibition rate (TGI) of 33% (60 mg/kg) and 52% (120 mg/kg) |

REFERENCES

[1]. Chen Y, et al., Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors. Eur J Med Chem. 2024 Jan 28;267:116171.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA